A Phase I/II Study of Intensive Dose Escalation of Cytarabine in Combination with Idarubicin and Etoposide in Induction and Consolidation Treatment of Adult Acute Myeloid Leukemia

References

• Bishop J. F. The treatment of adult acute myeloid leukemia. Seminars in Oncology 1997; 24: 57–69
   PubMed Web of Science ®Google Scholar
• Bennan E., Heller G., Santorsa J., et al. Results of a randomized trial comparing idarubicin and cytosine arabino‐side with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood 1991; 77: 1666–1674
   PubMed Web of Science ®Google Scholar
• Vogler W. R., Velez‐Garcia E., Weiner R. S., et al. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastem Cancer Study Group study. Journal of Clinical Oncology 1992; 10: 1103–1111
   PubMed Web of Science ®Google Scholar
• Wiemik P. H., Banks P. L. C., Case D. C., Jr., et al. Cytarabine plus idarubicin or daunorubicin as induction and Consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood 1992; 79: 313–319
   PubMed Web of Science ®Google Scholar
• Bishop J. F., Lowenthal R. M., Joshua D., et al. Eto‐poside in acute nonlymphocytic leukemia. Blood 1990; 75: 27–32
   PubMed Web of Science ®Google Scholar
• Bishop J. R., Matthews J. P., Young G. A., et al. A randomized study of high‐dose cytarabine in induction in acute myeloid leukemia. Blood 1996; 87: 1710–1717
   PubMed Web of Science ®Google Scholar
• Vogler W. R., McCarley D. L., Stagg M., et al. A phase III trial of high‐dose cytosine arabinoside with or without etoposide in relapsed and refractory acute myelogenous leukemia. A Southeastern Cancer Study Group trial. Leukemia 1994; 8: 1847–1853
   PubMed Web of Science ®Google Scholar
• Plunkett W., Iacoboni S., Keating M. J. Cellular pharmacology and optimal therapeutic concentrations of 1–β‐(‐D)‐arabinofuranosylcytosine 5′‐triphosphate in leuke‐mic blasts during treatment of refractory leukemia with high dose 1–β‐(‐D)‐arabinofuranosylcytosine. Scandinavian Journal of Haematology 1986; 44: 51–59
   Google Scholar
• Rustum Y. M., Preisler H. D. Correlation between leukemic cell retention of 1–β‐D‐arabinofurano‐sylcytosine 5′‐triphosphate and response to therapy. Cancer Research 1979; 39: 42–49
   PubMed Web of Science ®Google Scholar
• Mayer R. J., Davis R. B., Schiffer C. A., et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. New England Journal of Medicine 1994; 331: 896–903
   PubMed Web of Science ®Google Scholar
• Weick J. K., Kopecky K. J., Appelbaum F. R., et al. A randomized investigation of high‐dose versus standard‐dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood 1996; 88: 2841–2851
   PubMed Web of Science ®Google Scholar
• Huang M. E., Ye Y. C., Chen S. R., et al. Use of all‐trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72: 567–572
   PubMed Web of Science ®Google Scholar
• Wiley J. S., Firkin F. C. Reduction of pulmonary toxicity by prednisolone prophylaxis during all‐trans retinoic acid treatment of acute promyelocytic leukemia. Leukemia 1995; 9: 774–778
   PubMed Web of Science ®Google Scholar
• Fenaux P., Degos L. Differentiation therapy for acute promyelocytic leukemia. New England Journal of Medicine 1997; 337: 1076–1077
   PubMed Web of Science ®Google Scholar
• Miller A. B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207–214
   PubMed Web of Science ®Google Scholar
• Anonymous. S‐PLUS User's Guide. Data Analysis Products Division, MathSoft, Seattle, WA 1997
   Google Scholar
• Anonymous. SPSS Advanced Statistics 7.5. SPSS Inc., Chicago, IL 1997
   Google Scholar
• Anonymous. SratXact3 for Windows. CYTEL Software Corporation, Cambridge, MA 1995
   Google Scholar
• Lowenthal R. M., Lambertenghi‐Deliliers G. Oral idarubicin as treatment for advanced myelodysplastic syndrome. Haematologica 1991; 76: 398–401
   PubMed Web of Science ®Google Scholar
• Stentoft J. The toxicity of cytarabine. Drug Safety 1990; 5: 7–27
   PubMed Web of Science ®Google Scholar
• Mehta J., Powles R., Singhal S., et al. Idarubicin, high‐dose cytarabine, and etoposide for induction of remission in acute leukemia. Seminars in Hematology 1996; 33(Suppl 3)18–23
   PubMed Web of Science ®Google Scholar
• Carella A. M., Carlier P., Pungolin E., et al. Idarubi‐cin in combination with intermediate‐dose cytarabine and VP‐16 in the treatment of refractory or rapidly relapsed patients with acute myeloid leukemia. Leukemia 1993; 7: 196–199
   PubMed Web of Science ®Google Scholar
• Baer M. R., Christiansen N. P., Frankel S. R., et al. High dose cytarabine, idarubicin, and granulocyte colony‐stimulating factor remission induction therapy for previously untreated de novo and secondary adult acute myeloid leukemia. Seminars in Oncology 1993; 20(Suppl 8)6–12
   PubMed Web of Science ®Google Scholar
• Harousseau J. L., Pignon B., Witz F., et al. Treatment of acute myeloblastic leukemia in adults. The GOELAM experience. Hematology and Cell Therapy 1996; 38: 381–391
   PubMedGoogle Scholar
• Ohno R., Tomonaga M., Kobayashi T., et al. Effect of granulocyte colony‐stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. New England Journal of Medicine 1990; 323: 871–877
   PubMed Web of Science ®Google Scholar
• Ohno R., Naoe T., Kanamaru A., et al. A double‐blind controlled study of granulocyte colony‐stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia. Blood 1994; 83: 2086–2092
   PubMed Web of Science ®Google Scholar
• Estey E., Thall P., Andreeff M., et al. Use of granulocyte coIony‐stimulating factor before, during, and after flu‐darabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony‐stimulating factor. Journal of Clinical Oncology 1994; 12: 671–678
   PubMed Web of Science ®Google Scholar
• Heil G., Hoelzer D., Sanz M. A., et al. A randomized, double‐blind placebo‐controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. Blood 1997; 90: 4710–4718
   PubMed Web of Science ®Google Scholar
• Geller R. B. Use of cytokines in the treatment of acute myelocytic leukemia: a critical review. Journal of Clinical Oncology 1996; 14: 1371–1382
   PubMed Web of Science ®Google Scholar
• Dombret H., Chastang C., Fenaux P., et al. A controlled study of recombinant human granulocyte colony‐stimulating factor in elderly patients after treatment for acute myelogenous leukemia. New England Journal of Medicine 1995; 332: 1678–1683
   PubMed Web of Science ®Google Scholar
• Chi K. ‐H., Chen C. ‐H., Chan W. ‐K., et al. Effect of granulocyte‐macrophage colony‐stimulating factor on oral mucositis in head and neck cancer patients after cisplatin, fluorouracil and leucovorin chemotherapy. Journal of Clinical Oncology 1995; 13: 2620–2628
   PubMed Web of Science ®Google Scholar
• Bishop J. F. Intensified therapy for acute myeloid leukemia. New England Journal of Medicine 1994; 331: 941–942
   PubMed Web of Science ®Google Scholar
• Keating S., Suciu S., de Witte T., et al. Prognostic factors of patients with acute myeloid leukemia (AML) allografted in first complete remission: an analysis of the EORTC‐GIMEMA AML 8A trial. Bone Marrow Transplantation 1996; 17: 993–1001
   PubMed Web of Science ®Google Scholar
• Bishop J. F., Matthews J. P., Young G. A. R., Bradstock K., Lowenthal R. M. Intensified induction chemotherapy with high dose cytarabine and etoposide for acute rnyeloid leukemia: a review and updated results of Australian Leukaemia Study Group. Leukemia and Lymphoma 1998; 28: 315–327
   PubMed Web of Science ®Google Scholar